Dr. Zhang will lead the expansion of our current clinical cancer genomic offerings to support integrated clinical cancer care for the UCLA Health System, and to identify, support and advance UCLA translational research into clinical use and technology transfer.
Dr. Zhang’s research focuses on identifying the genetic alterations in human cancers and the biomarkers of cancer progression and drug response through comprehensive molecular profiling and analysis of tumors. Another area of Dr. Zhang’s interests is the identification and characterization of germline mutations in patients with solid tumor and hematologic malignancies that have immediate clinical applications for guiding treatment decisions such as PARP inhibitors in breast, ovarian, pancreatic and prostate cancers, and inherited risk assessment for patient and their families.